home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9602.ZIP
/
M9620455.TXT
< prev
next >
Wrap
Text File
|
1996-02-26
|
3KB
|
48 lines
Document 0455
DOCN M9620455
TI Testicular germ cell tumors and human immunodeficiency virus infection:
a report of 26 cases. Italian Cooperative Group on AIDS and Tumors.
DT 9602
AU Bernardi D; Salvioni R; Vaccher E; Repetto L; Piersantelli N; Marini B;
Talamini R; Tirelli U; Division of Medical Oncology and AIDS, Centro di
Riferimento; Oncologico, Aviano, Italy.
SO J Clin Oncol. 1995 Nov;13(11):2705-11. Unique Identifier : AIDSLINE
MED/96067227
AB PURPOSE: Besides tumors that are diagnostic of AIDS, such as
non-Hodgkin's lymphoma, Kaposi's sarcoma, and invasive carcinoma of the
cervix, other tumors have been described in the human immunodeficiency
virus (HIV) setting. Some case reports on testicular cancer in
HIV-infected patients have appeared in the literature. We present a
retrospective study on 26 cases of testicular germ cell tumors (TGCTs)
observed within the Italian Cooperative Group on AIDS and Tumors (GICAT)
between November 1986 and September 1994. PATIENTS AND METHODS:
Twenty-six patients with TGCT and HIV-infection from the GICAT were
retrospectively analyzed. RESULTS: Fourteen patients had seminoma and 12
had nonseminoma. Four patients underwent only orchidectomy, one patient
received only chemotherapy, nine patients were treated with postsurgical
chemotherapy, 10 patients (38%) received postsurgical radiotherapy, one
patient received postsurgical chemotherapy plus radiotherapy, and one
patient was lost for follow-up evaluation immediately after diagnosis.
The complete response (CR) rate was 95%. Relapse occurred in 32% of
patients. The median follow-up time was 33 months. The mortality rate
was 37%. Causes of death were neoplasia in three of nine patients, AIDS
in five of nine patients, and fortuitous event in one of nine patients.
The overall 3-year survival rate was 65%, and the 3-year disease-free
survival rate was 65%. Severe hematologic toxicity was observed in seven
of 15 patients. CONCLUSION: HIV-infected patients with testicular cancer
should be offered standard oncologic therapy, irrespective of their HIV
status, since the majority can be cured of their tumor and have a good
quality of life. Use of concomitant prophylaxis for opportunistic
infections is recommended.
DE Adult Antineoplastic Agents, Combined/THERAPEUTIC USE Combined
Modality Therapy Disease-Free Survival Follow-Up Studies
Germinoma/*ETIOLOGY/MORTALITY/THERAPY Human HIV
Infections/*COMPLICATIONS Italy Male Remission Induction
Retrospective Studies Support, Non-U.S. Gov't Survival Rate
Testicular Neoplasms/*ETIOLOGY/MORTALITY/THERAPY JOURNAL ARTICLE
MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).